

May 07, 2026

National Stock Exchange of India Limited  
Exchange Plaza  
Bandra Kurla Complex,  
Bandra (E), Mumbai - 400051  
**(SYMBOL: THYROCARE)**

BSE Limited  
Phiroze Jeejeeboy Towers  
Dalal Street,  
Mumbai- 400001  
**(SCRIP CODE: 539871)**

**Subject: Audited Financial Results (Standalone & Consolidated) for the quarter and financial year ended on March 31, 2026**

Dear Sir/Madam,

Pursuant to the provisions of Regulation 30 and other applicable provisions of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“**Listing Regulations**”), please find enclosed copies of the Audited Standalone and Consolidated financial results for the quarter and financial year ended March 31, 2026, along with the Auditors’ Report on the said financial results issued by the Statutory Auditors of the Company as **Annexure-1**.

The Statutory Auditors of the Company, M/s. M S K A & Associates LLP, Chartered Accountants have issued an unmodified opinion on the Audited Financial Results (standalone & consolidated) for the quarter and financial year ended March 31, 2026.

A declaration from the Chief Financial Officer confirming that the Audit Reports on the said financial results contain an unmodified opinion is enclosed as **Annexure – 2**.

The aforesaid Audited Financial Results and Auditors’ Report are also being made available on the website of the Company at <https://investor.thyrocare.com/financials/quarterly-financial-results/>

**The Board Meeting commenced at 03:35 P.M. and concluded at 05:40 P.M.**

This is for your information and records.

Yours Faithfully,  
For **Thyrocare Technologies Limited**,



**Brijesh Kumar**  
Company Secretary and Compliance Officer  
Encl. A/a

## INDEPENDENT AUDITOR'S REPORT

To the Board of Directors of Thyrocare Technologies Limited

Report on the Audit of the Standalone Annual Financial Results

### Opinion

We have audited the accompanying Standalone Annual Financial Results of Thyrocare Technologies Limited (hereinafter referred to as 'the Company') for the year ended March 31, 2026, ('the Statement'), attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('Listing Regulations').

In our opinion and to the best of our information and according to the explanations given to us the aforesaid Statement:

(i) is presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and

(ii) gives a true and fair view, in conformity with the recognition and measurement principles laid down in the applicable accounting standards prescribed under Section 133 of the Companies Act, 2013 ('the Act'), read with Companies (Indian Accounting Standards) Rules, 2015, as amended, and other accounting principles generally accepted in India, of the net profit, and other comprehensive income and other financial information of the Company for the year ended March 31, 2026.

### Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing ('SAs') specified under section 143(10) of the Act. Our responsibilities under those SAs are further described in the Auditor's Responsibilities for the Audit of the Standalone Financial Results section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the Standalone Financial Statements under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our opinion.

### Management's and Board of Directors' Responsibilities for the Standalone Financial Results

This Statement has been prepared on the basis of the Standalone Annual Financial Statements. The Company's Management and Board of Directors are responsible for the preparation and presentation of this Statement that gives a true and fair view of the net profit, and other comprehensive income and other financial information in accordance with the recognition and measurement principles laid down in the applicable Accounting Standards prescribed under Section 133 of the Act read with Companies (Indian



# MSKA & Associates LLP

(Formerly known as M S K A & Associates)

Chartered Accountants

Accounting Standards) Rules, 2015, as amended and other accounting principles generally accepted in India and is in compliance with the Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and

application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Statement that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the Statement, the Board of Directors of the Company are responsible for assessing the ability of the Company to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are also responsible for overseeing the financial reporting process of the Company.

## Auditor's Responsibilities for the Audit of the Standalone Financial Results

Our objectives are to obtain reasonable assurance about whether the Statement as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this Statement.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Statement, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3) (i) of the Act, we are also responsible for expressing our opinion on whether the Company has adequate internal financial controls with reference to Standalone Financial Statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.



# MSK A & Associates LLP

(Formerly known as M S K A & Associates)

Chartered Accountants

- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Company to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Statement or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the Statement, including the disclosures, and whether the Statement represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance of the Company regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

## Other Matter(s):

The Statement includes the results for the quarter ended March 31, 2026 being the balancing figure between the audited figures in respect of the full financial year ended March 31, 2026 and the published unaudited year to date figures up to the third quarter of the current financial year which were subject to limited review by us.

**For M S K A & Associates LLP (Formerly known as M S K A & Associates)**

Chartered Accountants

ICAI Firm Registration No.105047W/W101187



Ojas D. Joshi

Partner

Membership No.: 109752

UDIN: 26109752KPBHAI3153



Place: Navi Mumbai

Date: May 07, 2026

**THYROCARE TECHNOLOGIES LIMITED**

Registered Office: D/37-1, TTC Industrial Area, MIDC Turbhe, Navi Mumbai 400 703

Corporate Office: D/37-3, TTC Industrial Area, MIDC Turbhe, Navi Mumbai 400 703

Tel: (91 22) 2762 2762 | Fax: (91 22) 2768 2409

Website: www.thyrocare.com

E-mail: kumar.brijesh@thyrocare.com

Corporate Identity Number: L85110MH2000PLC123882

**Statement of Audited Standalone Financial Results for the Quarter and Year Ended 31 March 2026**

(Rs. in Crores)

Particulars	Quarter ended			Year ended	Year ended
	31 March 2026 (Audited)	31 December 2025 (Reviewed)	31 March 2025 (Audited)	31 March 2026 (Audited)	31 March 2025 (Audited)
Revenue from operations	210.67	182.48	173.87	774.27	633.10
Other Income	3.72	3.43	4.54	13.39	13.34
<b>1 Total income</b>	<b>214.39</b>	<b>185.91</b>	<b>178.41</b>	<b>787.66</b>	<b>646.44</b>
<b>Expenses</b>					
(a) Cost of materials consumed	54.27	44.61	46.19	208.37	177.28
(b) Purchase of stock-in-trade	0.77	0.04	0.46	1.09	2.00
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(0.51)	0.09	0.30	(0.23)	0.81
(d) Employee benefits expense	33.44	32.78	31.33	128.29	118.56
(e) Finance cost	1.43	(0.47)	0.60	2.18	2.63
(f) Depreciation and amortisation expense	12.94	19.58	11.78	51.17	46.52
(g) Other expenses	50.07	46.69	39.95	180.42	147.43
<b>2 Total Expenses</b>	<b>152.41</b>	<b>143.32</b>	<b>130.61</b>	<b>571.29</b>	<b>495.23</b>
<b>3 Profit before exceptional items and tax (1 - 2)</b>	<b>61.98</b>	<b>42.59</b>	<b>47.80</b>	<b>216.37</b>	<b>151.21</b>
Exceptional Items	-	5.97	-	5.97	-
<b>4 Profit after exceptional items and before tax</b>	<b>61.98</b>	<b>36.62</b>	<b>47.80</b>	<b>210.40</b>	<b>151.21</b>
<b>5 Tax expense</b>					
(a) Current tax expense (including adjustment of earlier years)	(16.05)	(9.95)	(14.43)	(57.29)	(47.77)
(b) Deferred tax credit/(charge) (refer to note 4 below)	(2.35)	(0.52)	(11.42)	(4.30)	(7.66)
<b>6 Profit for the period/year (4 - 5)</b>	<b>43.58</b>	<b>26.15</b>	<b>21.95</b>	<b>148.81</b>	<b>95.78</b>
<b>7 Other comprehensive income (net of tax)</b>					
(a) Items that will not be reclassified to profit or loss	0.64	(0.16)	(0.31)	0.29	(0.97)
(b) Income tax relating to items that will not be reclassified to profit or loss	(0.16)	0.04	0.08	(0.07)	0.24
<b>8 Total comprehensive income for the period/ year comprising of profit and other comprehensive income for the period/ year (6 + 7)</b>	<b>44.06</b>	<b>26.03</b>	<b>21.72</b>	<b>149.03</b>	<b>95.05</b>
Paid-up equity share capital (Face Value of Rs. 10/- each)	159.17	159.16	52.99	159.17	52.99
Other equity	-	-	-	401.51	484.11
<b>9 Earnings Per Share (of Rs. 10/- each):#</b>					
(a) Basic ( in Rs.)	2.75	1.64	1.36	9.36	5.98
(b) Diluted ( in Rs.)	2.75	1.63	1.35	9.34	5.96
See accompanying note to the Financial Results					

#not annualised except for the year ended 31 March 2026 and 31 March 2025.

**Notes :**

- The above audited standalone financial results of the Company were audited and recommended by the Audit Committee on 7 May 2026 and subsequently approved by the Board of Directors at its meeting held on 7 May 2026. The statutory auditors of the Company have expressed an unmodified opinion on the audited standalone financial results for the quarter and year ended 31 March 2026.
- The figures for the quarter ended 31 March 2026 and 31 March 2025 are the balancing figures between audited figures in respect of the full financial year and the limited reviewed year to date figures up to the quarter ended 31 December 2025 and 31 December 2024 respectively.
- These audited standalone financial results have been prepared in compliance with the recognition and remasurement principles of Ind AS as notified by the Ministry of Corporate Affairs and prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder and other accounting pronouncements generally accepted in India, to the extent applicable.
- The Company has assessed the recoverable amount of the investment made in its wholly owned subsidiary Nuclear Healthcare Limited ('NHL') as value in use, being the higher of Fair Value less Cost of Disposal and Value in Use. For the year ended 31 March 2026, NHL has reported earning before interest tax and depreciation of Rs.6.15 Crores and has generated cash inflow from operating activities amounting to Rs. 10.67 Crores. NHL still has accumulated losses carried forward from the previous years, hence the Company continues to assess the profitability and growth of NHL. The management does not foresee any further requirement of impairment of its investment made in NHL as at 31 March 2026 other than those already provided for in the books of account amounting to Rs. 44.33 Crores (31 March 2025: INR 44.33 Crores). The deferred tax asset created against the impairment of investment made in NHL in the earlier financial years amounting to Rs. 11.16 Crores has been reversed in the previous financial year. The impact of the same is forming part of previous year deferred tax charge.



5 Effective 21 November 2025, The Government of India has consolidated multiple existing labour laws into an unified framework comprising four Labour Codes viz the Code on Wages, 2019, the Code on Social Security, 2020, the Industrial Relations Code, 2020, and the Occupational Safety, Health and Working Conditions Code, 2020 collectively referred to as the 'New Labour Codes'. The Ministry of Labour & Employment published draft Central Rules and FAQs to enable assessment of the financial impact due to changes in regulations.

The Company has assessed the incremental impact of these changes on the basis of the information available and actuarial valuation report obtained from an independent valuer, consistent with the guidance provided by the Institute of Chartered Accountants of India. Considering the materiality, its origination due to regulatory changes and non-recurring nature of this impact, the Company has presented such incremental impact as "Exceptional Items" in the audited standalone financial results for the year ended 31 March 2026. Accordingly the Exceptional Items includes of Rs. 4.01 Crores as incremental impact of Gratuity arising primarily due to the change in the definition of wages.

Further Exceptional Items also include Rs. 1.96 Crores which are non recurring costs associated with restructuring of capital during the year ended 31 March 2026.

- 6 During the quarter and year ended 31 March 2026, the Company has forfeited 5,196 equity stock options and 25,172 equity stock options respectively granted to employees under Employee Stock Option schemes but not vested on account of discontinuance of services of these employees, which has been added back to the pool and the same would be available for subsequent distribution subject to statutory rules and regulations, as applicable.
- 7 During the year ended 31 March 2026, the Company has allotted 63,074 equity shares of Rs.10/- each pursuant to the exercise of options by the grantees under the Employee Stock Option Scheme.
- 8 In accordance with Ind AS 108 'Operating Segments', segment information has been given in the unaudited consolidated financial results of the Group.
- 9 The earning per share in respect of previous quarters / years has been restated considering the allotment of bonus shares and adjustment in respect of outstanding stock options, in line with the requirements of Ind AS 33 "Earnings Per Share".
- 10 The Board of directors have recommended a final dividend of Rs. 7 per equity share of face value of Rs. 10 each for the year ended 31 March 2026 subject to the approval of shareholders at the ensuing shareholders meeting.
- 11 The audited standalone financial results are available on the website of the Company ([www.thyrocare.com](http://www.thyrocare.com)) and on the websites of BSE ([www.bseindia.com](http://www.bseindia.com)) and NSE ([www.nseindia.com](http://www.nseindia.com)).

By order of the Board  
For Thyrocare Technologies Limited  
CIN - L85110MH2000PLC123882



**Rahul Guha**  
Managing Director

DIN - 09588432  
Navi Mumbai, 7 May 2026

**Audited Standalone Statement of Assets and Liabilities as at 31 March 2026**

(Rs. in Crores)

Particulars		As at 31 March 2026 (Audited)	As at 31 March 2025 (Audited)
<b>A</b>	<b>ASSETS</b>		
<b>i</b>	<b>Non-current assets</b>		
(a)	Property, plant and equipment	113.56	113.66
(b)	Capital-work-in progress	3.07	14.17
(c)	Investment property	0.92	0.96
(d)	Goodwill	4.18	4.18
(e)	Other intangible assets	3.35	4.54
(f)	Right-of-use assets	58.40	34.21
(g)	Investment in associate and jointly controlled entity	20.00	23.12
(h)	<b>Financial assets</b>		
	Investments	167.04	156.71
	Other financial assets	5.60	6.63
(i)	Deferred tax assets (net)	12.71	17.08
(j)	Other tax assets	4.15	1.10
(k)	Other non-current assets	2.42	1.43
		<b>395.40</b>	<b>377.79</b>
<b>ii</b>	<b>Current assets</b>		
(a)	Inventories	46.56	45.70
(b)	<b>Financial assets</b>		
	Investments	106.83	103.97
	Trade receivables	69.53	68.94
	Cash and cash equivalents	32.88	15.18
	Bank balances other than cash and cash equivalents	29.75	36.80
	Other financial assets	1.21	1.04
(c)	Other current assets	29.05	26.93
		<b>315.81</b>	<b>298.56</b>
	<b>TOTAL ASSETS</b>	<b>711.21</b>	<b>676.35</b>
<b>B</b>	<b>EQUITY</b>		
i	Equity share capital	159.17	52.99
ii	Other equity	401.51	484.11
	<b>Total Equity</b>	<b>560.68</b>	<b>537.10</b>
<b>C</b>	<b>LIABILITIES</b>		
<b>i</b>	<b>Non-current liabilities</b>		
(a)	<b>Financial liabilities</b>		
	Lease liabilities	38.32	16.70
(b)	Provisions	11.79	5.00
(c)	Other financial liabilities	5.00	6.59
		<b>55.11</b>	<b>28.29</b>
	<b>Current liabilities</b>		
(a)	<b>Financial liabilities</b>		
	Short-term borrowings	-	-
	Lease liabilities	9.86	6.51
	Trade payables		
	<i>Total outstanding dues to micro and small enterprises</i>	5.76	2.56
	<i>Total outstanding dues to creditors other than micro and small enterprises</i>	49.37	67.04
	Other financial liabilities	12.77	14.32
(b)	Contract Liabilities	10.60	13.56
(c)	Current tax liabilities (net)	2.38	2.38
(d)	Provisions	1.25	0.98
(e)	Other current liabilities	3.43	3.61
		<b>95.42</b>	<b>110.96</b>
	<b>TOTAL EQUITY AND LIABILITIES</b>	<b>711.21</b>	<b>676.35</b>

By order of the Board  
For Thyrocare Technologies Limited  
CIN - L85110MH2000PLC123882



*Rahul Guha*

**Rahul Guha**  
Managing Director  
DIN - 09588432  
Navi Mumbai, 7 May 2026

**Audited Standalone Statement of Cash Flows for the Year ended 31 March 2026**

(Rs. in Crores)

Particulars		As at 31 March 2026 (Audited)	As at 31 March 2025 (Audited)
<b>A.</b>	<b>Cash flows from operating activities</b>		
	Net profit before exceptional items and income tax	210.40	151.21
	Adjustments for:		
	Depreciation and amortisation	51.17	46.52
	Net (gain) on investments	(0.30)	(0.72)
	(Profit)/Loss on sale of property, plant and equipment	(3.10)	(0.01)
	Impairment loss allowance on financial assets	(2.15)	1.07
	Employee stock compensation expense	22.56	23.48
	Finance costs	2.15	2.65
	Interest income	(3.06)	(1.38)
	Profit on sale of short term investment	(5.14)	-
	<b>Total of Profit &amp; Loss adjustment</b>	<b>62.13</b>	<b>71.61</b>
	<b>Operating profit before working capital changes</b>	<b>272.53</b>	<b>222.82</b>
	Adjustments for:		
	(Increase) in Inventories	(0.86)	(0.00)*
	Decrease / (Increase) in Trade receivables	1.57	(29.81)
	Decrease/(Increase) in Other assets	4.77	(5.44)
	(Decrease)/Increase in Trade payables	(14.75)	33.65
	(Decrease)/Increase in Other liabilities	(2.67)	5.44
	Increase in Provisions	5.77	0.98
	<b>Net Working Capital Movement</b>	<b>(6.17)</b>	<b>4.82</b>
	Cash generated from operations	266.36	227.64
	Tax paid (net of refunds)	(60.29)	(49.00)
	<b>Net cash flows generated from operating activities (A)</b>	<b>206.07</b>	<b>178.64</b>
<b>B.</b>	<b>Purchase of property, plant and equipment, additions to capital work-in-progress and capital advances</b>	<b>(18.93)</b>	<b>(34.83)</b>
	Proceeds from sale of property, plant and equipment	4.06	0.01
	Sale/(Purchase) of current investments (net)	2.87	12.01
	Consideration paid on acquisition of Polo & Vimta Business	-	(11.26)
	Investment in associate and jointly controlled entity	(7.22)	(3.63)
	(Investment in)/proceeds from maturity of term deposits	(4.76)	(6.27)
	Interest received	3.06	1.39
	<b>Net cash (used in) investing activities (B)</b>	<b>(20.92)</b>	<b>(42.58)</b>
	<b>Cash flows from financing activities</b>		
	Proceeds from issue of equity shares	-	0.04
	Repayment of borrowings	-	(19.76)
	Payment towards principal portion of lease liabilities	(16.87)	(6.76)
	Payment towards interest portion of lease liabilities	(2.15)	(2.22)
	Interest Paid	-	(0.43)
	Dividend paid to the shareholders	(148.43)	(95.31)
	<b>Net cash (used in) financing activities (C)</b>	<b>(167.45)</b>	<b>(124.44)</b>
	Net Increase in Cash and cash equivalents (A+B+C)	17.70	11.62
	Cash and cash equivalents at the beginning of the year	15.18	3.56
	<b>Cash and cash equivalents at the end of the year</b>	<b>32.88</b>	<b>15.18</b>

\*represents value less than Rs. 0.01 crores.

By order of the Board  
For Thyrocare Technologies Limited  
CIN - L85110MH2000PLC123882



*Rahul Guha*

**Rahul Guha**  
Managing Director  
DIN - 09588432

Navi Mumbai, 7 May 2026

# MSK A & Associates LLP

(Formerly known as M S K A & Associates)

Chartered Accountants

HO  
602, Floor 6, Raheja Titanium  
Western Express Highway, Geetanjali  
Railway Colony, Ram Nagar, Goregaon (E)  
Mumbai 400063, INDIA  
Tel: +91 22 6974 0200

## INDEPENDENT AUDITOR'S REPORT

To the Board of Directors of Thyrocare Technologies Limited

Report on the Audit of the Consolidated Annual Financial Results

### Opinion

We have audited the accompanying Consolidated Annual Financial Results of Thyrocare Technologies Limited (hereinafter referred to as the 'Holding Company') and its subsidiaries (Holding Company and its subsidiaries together referred to as "the Group"), its associate for the year ended March 31, 2026, ('the Statement') attached herewith, being submitted by the Holding Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('Listing Regulations').

In our opinion and to the best of our information and according to the explanations given to us, and based on the consideration of reports of other auditors on separate audited Financial Statements of the subsidiaries and associate, the aforesaid Statement:

(a) includes the annual financial results of the Holding Company and the following entities:

Sr. No.	Name of the Entity	Relationship with the Holding Company
1.	Nuclear Healthcare Limited	Wholly Owned Subsidiary
2.	Think Health Diagnostic Private Limited	Wholly Owned Subsidiary
3.	Pulse Hitech Health Services (Ghatkopar) LLP	Subsidiary
4.	Thyrocare Laboratories (Tanzania) Limited	Subsidiary
5.	Equinox Labs Private Limited	Associate

(ii) is presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and

(iii) gives a true and fair view in conformity with the recognition and measurement principles laid down in the applicable accounting standards prescribed under Section 133 of the Companies Act, 2013 ('the Act'), read with Companies (Indian Accounting Standards) Rules, 2015, as amended, and other accounting principles generally accepted in India, of the consolidated net profit, and consolidated other comprehensive income and other financial information of the Group, its associate for the year ended March 31, 2026.



# MSK A & Associates LLP

(Formerly known as M S K A & Associates)

Chartered Accountants

## Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing ('SAs') specified under section 143(10) of the Act. Our responsibilities under those SAs are further described in the Auditor's Responsibilities for the Audit of the consolidated financial results section of our report. We are independent of the Group, its associate in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the Consolidated Financial Statements under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence obtained by us and other auditors in terms of their reports referred to in "Other Matters" paragraph below, is sufficient and appropriate to provide a basis for our opinion.

## Management and Board of Directors' Responsibilities for the Consolidated Financial Results

This Statement has been prepared on the basis of the Consolidated Annual Financial Statements. The Holding Company's Management and Board of Directors are responsible for the preparation and presentation of this Statement that gives a true and fair view of the consolidated net profit, and consolidated other comprehensive income and other financial information of the Group, its associate in accordance with the recognition and measurement principles laid down in the applicable Accounting Standards prescribed under Section 133 of the Act read with Companies (Indian Accounting Standards) Rules, 2015, as amended and other accounting principles generally accepted in India and is in compliance with the Regulation 33 of the Listing Regulations. The respective Board of Directors of the companies included in the Group and of its associate are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of each company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Statement that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of the Statement by the Management and Board of Directors of the Holding Company, as aforesaid.

In preparing the Statement, the respective Board of Directors of the companies included in the Group and of its associate are responsible for assessing the ability of the Group and its associate to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the respective Board of Directors either intends to liquidate the company or to cease operations, or has no realistic alternative but to do so.

The respective Board of Directors of the companies included in the Group and of its associate are responsible for overseeing the financial reporting process of each company.



# MSK A & Associates LLP

(Formerly known as M S K A & Associates)

Chartered Accountants

## Auditor's Responsibilities for the Audit of the Consolidated Financial Results

Our objectives are to obtain reasonable assurance about whether the Statement as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this Statement.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Statement, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3) (i) of the Act, we are also responsible for expressing our opinion on whether the Holding Company has adequate internal financial controls with reference to consolidated financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Group and its associate to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Statement or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group and its associate to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the Statement, including the disclosures, and whether the Statement represent the underlying transactions and events in a manner that achieves fair presentation.
- Obtain sufficient appropriate audit evidence regarding the financial results of the entities within the Group and its associate to express an opinion on the Statement. We are responsible for the direction, supervision and performance of the audit of financial information of such entities included in the Statement of which we are the independent auditors. For the other entities included in the Statement, which have been audited by other auditors, such other auditors remain responsible for the direction, supervision and performance of the audits carried out by them. We remain solely responsible for our audit opinion.

Page 3 of 5



Registered Office: 602, Raheja Titanium, Western Express Highway, Goregaon (East), Mumbai-400063, Maharashtra, India

Tel: +91 22 6974 0200 | LLPIN: ACT-3789

Ahmedabad | Bengaluru | Chandigarh | Chennai | Coimbatore | Goa | Gurugram | Hyderabad | Kochi | Kolkata | Mumbai | Pune [www.mska.in](http://www.mska.in)

# MSKA & Associates LLP

(Formerly known as M S K A & Associates)

Chartered Accountants

We communicate with those charged with governance of the Holding Company and such other entities included in the Statement of which we are the independent auditors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

We also performed procedures in accordance with the circular issued by SEBI under Regulation 33(8) of the Listing Regulations, to the extent applicable.

## Other Matters:

The Statement includes the audited Financial Statements of two subsidiaries whose Financial Statements reflect total assets of Rs. 7.77 Crores as at March 31, 2026, total revenue of Rs. 8.53 Crores, net loss after tax of Rs. 0.18 Crores, total comprehensive loss of Rs. 0.18 Crores and net cash inflow of Rs. 0.17 Crores for the year ended on that date respectively, as considered in the Statement, which have been audited by the other auditors. The other auditors' reports on the Financial Statements of these entities have been furnished to us by the management and our opinion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, is based solely on the reports of such other auditors and the procedures performed by us are as stated in paragraph above.

The Statement includes the audited Financial Statements of one associate whose Financial Statements reflect Group's share of net profit after tax of Rs. 1.39 Crores, and Group's share of total comprehensive income of Rs. 1.39 Crores for the year ended March 31, 2026, as considered in the Statement, which have been audited by the other auditor. The other auditor's reports on the Financial Statements of these entities have been furnished to us by the management and our opinion on the Statement, in so far as it relates to the amounts and disclosures included in respect of this associate is based solely on the report of such other auditor and the procedures performed by us are as stated in paragraph above.

The Statement includes the unaudited Financial Information of one foreign subsidiary whose Financial Information reflect total assets of Rs. 6.40 Crores as at March 31, 2026, total revenue of Rs. 2.73 Crores, net loss after tax of Rs. 4.53 Crores, total comprehensive loss of Rs. 4.53 Crores, and net cash inflow of Rs. 2.50 Crores for the year ended on that date respectively, as considered in the Statement. These unaudited Financial Information have been furnished to us by the Management and our opinion on the Statement, in so far as it relates to the amounts and disclosures included in respect of this subsidiary is based solely on such unaudited Financial Information. In our opinion and according to the information and explanations given to us by the Management, these Financial Information are not material to the Group.

Our opinion on the Statement is not modified in respect of the above matters with respect to our reliance on the work done and the reports of the other auditors and the Financial Information certified by the Board of Directors.



# MSK A & Associates LLP

(Formerly known as M S K A & Associates)

Chartered Accountants

The Statement includes the results for the quarter ended March 31, 2026 being the balancing figure between the audited figures in respect of the full financial year ended March 31, 2026 and the published unaudited year to date figures up to the third quarter of the current financial year which were subject to limited review by us.

For M S K A & Associates LLP (Formerly known as M S K A & Associates)

Chartered Accountants

ICAI Firm Registration No. 105047W/W101187



Ojas D. Joshi

Partner

Membership No.: 109752

UDIN: 26109752PZM QPB 2735

Place: Navi Mumbai

Date: May 07, 2026



**THYROCARE TECHNOLOGIES LIMITED**

Registered Office: D/37-1, TTC Industrial Area, MIDC Turbhe, Navi Mumbai 400 703

Corporate Office: D/37-3, TTC Industrial Area, MIDC Turbhe, Navi Mumbai 400 703

Tel: (91 22) 2762 2762 | Fax: (91 22) 2768 2409

Website: www.thyrocare.com

E-mail: kumar.brijesh@thyrocare.com

Corporate Identity Number: L85110MH2000PLC123882

**Statement of Audited Consolidated Financial Results for the Quarter and Year Ended 31 March 2026**

(Rs. in Crores)

Particulars	Quarter ended			Year ended	Year ended
	31 March 2026 (Audited)	31 December 2025 (Reviewed)	31 March 2025(Audited)	31 March 2026 (Audited)	31 March 2025 (Audited)
Revenue from operations	223.95	195.53	187.16	829.04	687.35
Other Income	4.31	4.98	4.59	16.99	14.83
<b>1 Total income</b>	<b>228.26</b>	<b>200.51</b>	<b>191.75</b>	<b>846.03</b>	<b>702.18</b>
<b>Expenses</b>					
(a) Cost of materials consumed	56.42	47.07	48.71	218.71	188.27
(b) Purchase of stock-in-trade	0.77	0.04	0.46	1.09	2.00
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(0.51)	0.09	0.30	(0.23)	0.81
(d) Employee benefits expense	36.07	35.76	33.47	138.06	126.77
(e) Finance cost	1.52	(0.09)	0.70	2.80	3.05
(f) Depreciation and amortisation expense	14.03	21.63	13.77	58.58	55.26
(g) Other expenses	56.11	54.74	46.52	209.37	179.14
<b>2 Total Expenses</b>	<b>164.41</b>	<b>159.24</b>	<b>143.93</b>	<b>628.38</b>	<b>555.30</b>
<b>3 Profit before exceptional items, share of profit/ (loss) of associate and jointly controlled entity and income tax</b>	<b>63.85</b>	<b>41.27</b>	<b>47.82</b>	<b>217.65</b>	<b>146.88</b>
Exceptional Items	-	6.16	-	6.16	-
<b>4 Profit before share of profit/ (loss) of associate and jointly controlled entity and income tax</b>	<b>63.85</b>	<b>35.11</b>	<b>47.82</b>	<b>211.49</b>	<b>146.88</b>
Share of profit/ (loss) of associate and jointly controlled	0.58	0.28	(0.63)	1.39	(1.44)
<b>5 Profit before tax</b>	<b>64.43</b>	<b>35.39</b>	<b>47.19</b>	<b>212.88</b>	<b>145.44</b>
<b>6 Tax expense</b>					
(a) Current tax expense (including adjustment of earlier years)	(16.05)	(9.95)	(14.34)	(57.29)	(47.82)
(b) Deferred tax credit/(charge)	0.32	2.61	(11.28)	7.26	(6.87)
<b>7 Profit for the period/year (5 - 6)</b>	<b>48.70</b>	<b>28.05</b>	<b>21.57</b>	<b>162.85</b>	<b>90.75</b>
<b>8 Other Comprehensive income (net of tax)</b>					
(a) Items that will not be reclassified to profit or loss	0.88	(0.19)	(0.31)	0.50	(1.03)
(b) Income tax relating to items that will not be reclassified to profit or loss	(0.22)	0.05	0.08	(0.12)	0.26
<b>9 Total Comprehensive income for the period/ year comprising Profit and other comprehensive income for the period / year (7 + 8)</b>	<b>49.36</b>	<b>27.91</b>	<b>21.34</b>	<b>163.23</b>	<b>89.98</b>
<b>10 Profit/ (Loss) attributable to :</b>					
(a) Owners of the company	47.12	29.01	21.70	163.05	91.51
(b) Non-controlling interest	1.59	(0.96)	(0.13)	(0.19)	(0.76)
<b>11 Total comprehensive income attributable to :</b>	<b>48.71</b>	<b>28.05</b>	<b>21.57</b>	<b>162.86</b>	<b>90.75</b>
(a) Owners of the company	47.77	28.87	21.47	163.42	90.74
(b) Non-controlling interest	1.59	(0.96)	(0.13)	(0.19)	(0.76)
<b>12 Earnings Per Share (of Rs. 10/- each):#</b>	<b>49.36</b>	<b>27.91</b>	<b>21.34</b>	<b>163.23</b>	<b>89.98</b>
Paid-up equity share capital (Face Value of Rs. 10/- each)	159.16	159.16	52.99	159.17	52.99
Other equity	-	-	-	426.33	493.76
(a) Basic (in Rs.)	2.99	1.82	1.39	10.27	5.70
(b) Diluted (in Rs.)	2.98	1.81	1.38	10.24	5.69
See accompanying notes to the Financial Results					

#not annualised except for the year ended 31 March 2026 and 31 March 2025.

By order of the Board  
For Thyrocare Technologies Limited  
CIN - L85110MH2000PLC123882



*Rahul Guha*

**Rahul Guha**  
Managing Director  
DIN - 09588432  
Navi Mumbai, 7 May 2026

**Audited Consolidated Statement of Assets and Liabilities as at 31 March 2026**

(Rs. in Crores)

Particulars		As at 31 March 2026 (Audited)	As at 31 March 2025 (Audited)
<b>A</b>	<b>ASSETS</b>		
<b>i</b>	<b>Non-current assets</b>		
(a)	Property, plant and equipment	145.08	148.71
(b)	Capital-work-in progress	3.06	14.15
(c)	Goodwill	108.21	108.21
(d)	Other intangible assets	3.49	4.84
(e)	Right-of-use assets	60.54	35.45
(f)	Investment in associate and jointly controlled entity	25.14	24.17
(g)	<b>Financial assets</b>		
	Other financial assets	6.66	7.89
(h)	Deferred tax assets (net)	15.66	8.53
(i)	Other tax assets	4.31	1.65
(j)	Other non-current assets	2.78	1.43
		<b>374.93</b>	<b>355.03</b>
<b>ii</b>	<b>Current assets</b>		
(a)	Inventories	48.46	46.54
(b)	<b>Financial assets</b>		
	Investments	151.50	137.36
	Trade receivables	73.88	73.00
	Cash and cash equivalents	38.32	17.68
	Bank balances other than cash and cash equivalents	29.84	36.80
	Other financial assets	2.25	1.15
(c)	Other current assets	28.04	25.19
		<b>372.29</b>	<b>337.72</b>
	<b>TOTAL ASSETS</b>	<b>747.22</b>	<b>692.75</b>
<b>B</b>	<b>EQUITY</b>		
<b>i</b>	Equity share capital	159.17	52.99
<b>ii</b>	Other equity	426.33	493.76
<b>iii</b>	<b>Non-controlling interests</b>	0.52	0.30
	<b>Total Equity</b>	<b>586.02</b>	<b>547.05</b>
<b>C</b>	<b>LIABILITIES</b>		
<b>i</b>	<b>Non-current liabilities</b>		
(a)	<b>Financial liabilities</b>		
	Lease liabilities	39.18	16.92
(b)	Provisions	12.11	6.94
		<b>51.29</b>	<b>23.86</b>
<b>ii</b>	<b>Current liabilities</b>		
(a)	<b>Financial liabilities</b>		
	Lease liabilities	11.51	7.76
	Trade payables		
	<i>Total outstanding dues to micro and small enterprises</i>	5.98	2.81
	<i>Total outstanding dues to creditors other than micro and small enterprises</i>	59.39	73.40
	Other financial liabilities	14.45	16.60
(b)	Contract Liabilities	10.69	13.63
(c)	Current tax liabilities (net)	2.38	2.38
(d)	Provisions	1.46	1.00
(e)	Other current liabilities	4.05	4.26
		<b>109.91</b>	<b>121.84</b>
	<b>TOTAL EQUITY AND LIABILITIES</b>	<b>747.22</b>	<b>692.75</b>

By order of the Board  
For Thyrocare Technologies Limited  
CIN - L85110MH2000PLC123882



  
**Rahul Guha**  
 Managing Director  
 DIN - 09588432  
 Navi Mumbai, 7 May 2026

**Audited Consolidated Statement of Cash Flows for the Year ended 31 March 2026**

(Rs. in Crores)

Particulars		As at 31 March 2026 (Audited)	As at 31 March 2025 (Audited)
<b>A.</b>	<b>Cash flows from operating activities</b>		
	Net profit before exceptional items and income tax	212.88	146.88
	Adjustments for:		
	Depreciation and amortisation	58.58	55.26
	Net (gain) on investments	(2.57)	(1.09)
	(Profit)/ Loss on sale of property, plant and equipment	(4.08)	(0.01)
	(Profit) on sale of short term investment	(5.14)	(7.72)
	Impairment loss allowance on financial assets	(1.87)	1.26
	Gain on termination of lease	(0.07)	-
	Finance cost	2.77	3.06
	Interest Income on investments	-	(0.60)
	Employee stock compensation expense	24.09	24.51
	Interest income	(3.07)	(1.39)
	<b>Total of Profit &amp; Loss adjustment</b>	<b>68.64</b>	<b>73.28</b>
	<b>Operating profit before working capital changes</b>	<b>281.52</b>	<b>220.16</b>
	Adjustments for:		
	Decrease/(Increase) in Inventories	(1.92)	0.99
	(Increase)/Decrease in Trade receivables	(0.99)	(30.79)
	(Increase)/Decrease in Other assets	2.74	(26.75)
	Increase in Trade payables	(10.86)	36.10
	Increase in Other liabilities	(3.05)	30.28
	Increase/(Decrease) in Provisions	5.62	1.30
	<b>Net Working Capital Movement</b>	<b>(8.46)</b>	<b>11.13</b>
	Cash generated from operations	273.06	231.29
	Tax paid (net of refunds)	(59.82)	(51.38)
	<b>Net cash flows generated from operating activities (A)</b>	<b>213.24</b>	<b>179.91</b>
<b>B.</b>	<b>Cash flows from investing activities</b>		
	Purchase of property, plant and equipment, additions to capital work in progress and capital advances	(20.88)	(33.48)
	Proceeds from sale of property, plant and equipment	5.40	0.01
	Sale/(Purchase) of current investments (net)	(6.43)	8.20
	Consideration paid on acquisition of Polo and Vimta Business	-	(11.26)
	Investment in associate and jointly controlled entity	-	0.01
	(Investment in)/proceeds from maturity of term deposits	(4.17)	(6.56)
	Interest received	3.07	1.97
	<b>Net cash (used in) investing activities (B)</b>	<b>(23.01)</b>	<b>(41.11)</b>
<b>C.</b>	<b>Cash flows from financing activities</b>		
	Proceeds from issue of equity shares	-	0.04
	Repayment of borrowings	-	(21.59)
	Payment towards principal portion of lease liabilities	(18.39)	(10.49)
	Payment towards interest portion of lease liabilities	(2.77)	(2.64)
	Interest paid	-	(0.43)
	Dividend paid to the shareholders	(148.43)	(95.31)
	<b>Net cash (used in) financing activities (C)</b>	<b>(169.59)</b>	<b>(130.42)</b>
	Net Increase in Cash and cash equivalents (A+B+C)	20.64	8.38
	Cash and cash equivalents at the beginning of the year	17.68	9.30
	<b>Cash and cash equivalents at the end of the year</b>	<b>38.32</b>	<b>17.68</b>

By order of the Board  
For Thyrocare Technologies Limited  
CIN - L85110MH2000PLC123882



*Rahul Guha*

**Rahul Guha**  
Managing Director  
DIN - 09588432  
Navi Mumbai, 7 May 2026

**Notes:**

1 Based on the "management approach" as defined in Ind AS 108 - Operating Segments, the Chief Operating Decision Maker evaluates the Group's Performance. The Group has identified business segments as its primary segments. The Group recognizes its diagnostic testing services activity and imaging services including manufacturing of radiopharmaceuticals activity as its primary business segments. Diagnostic testing services operations predominantly consists of providing laboratory testing services to its customers. Imaging services segment represents PET-CT scan and sale of radio pharmaceuticals used in imaging services. Others represents trading and other related business activities. The accounting principles used in the preparation of the financial statements are consistently applied to record revenue and expenditure in individual segments.

(Rs. in Crores)

Particulars	Quarter ended			Year ended 31 March 2026 (Audited)	Year ended 31 March 2025 (Audited)
	31 March 2026 (Audited)	31 December 2025 (Reviewed)	31 March 2025(Audited)		
<b>Segment Revenue</b>					
Diagnostic Testing Services	210.22	182.41	172.69	772.53	629.69
Imaging Services	12.48	12.42	13.68	53.14	54.29
Others	1.24	0.70	0.79	3.37	3.37
Total	223.95	195.53	187.16	829.04	687.35
Less : Intersegment Revenue	-	-	-	-	-
<b>Revenue from Operations</b>	<b>223.95</b>	<b>195.53</b>	<b>187.16</b>	<b>829.04</b>	<b>687.35</b>
<b>Segment Results before tax, exceptional items, share of profit/loss of associate and jointly controlled entity and income tax</b>					
Diagnostic Testing Services	58.86	36.82	41.17	197.48	135.51
Imaging Services	(0.30)	(1.10)	2.02	0.67	(4.02)
Others	0.98	0.57	0.03	2.51	0.57
Total	59.54	36.29	43.22	200.66	132.06
Add : Unallocable income net off other unallocable expenditure	4.31	4.98	4.60	16.99	14.82
<b>Total Profit before exceptional items, share of profit/loss of associate and jointly controlled entity and income tax</b>	<b>63.85</b>	<b>41.27</b>	<b>47.82</b>	<b>217.65</b>	<b>146.88</b>
Exceptional items	-	(6.16)	-	(6.16)	-
Share of profit/ (loss) of associate and jointly controlled entity	0.58	0.28	(0.63)	1.39	(1.44)
<b>Profit before tax</b>	<b>64.43</b>	<b>35.39</b>	<b>47.19</b>	<b>212.88</b>	<b>145.44</b>
<b>Segment assets</b>					
Diagnostic Testing Services	514.08	476.57	480.54	514.08	480.54
Imaging Services	192.34	187.46	179.52	192.34	179.52
Others	-	-	-	-	-
Unallocated	40.80	40.11	32.69	40.80	32.69
	<b>747.22</b>	<b>704.14</b>	<b>692.75</b>	<b>747.22</b>	<b>692.75</b>
<b>Segment Liabilities</b>					
Diagnostic Testing Services	147.35	142.52	108.73	147.35	108.73
Imaging Services	11.47	14.86	10.73	11.47	10.73
Others	-	-	-	-	-
Unallocated	2.38	15.14	2.38	2.38	2.38
	<b>161.20</b>	<b>172.52</b>	<b>121.84</b>	<b>161.20</b>	<b>121.84</b>

- The above audited consolidated financial results of the Group were reviewed and recommended by the Audit Committee on 7 May 2026 and subsequently approved by the Board of Directors at its meeting held on 7 May 2026. The statutory auditors of the Group have expressed an unmodified opinion on the audited consolidated financial results for the quarter and year ended 31 March 2026.
- The figures for the quarter ended 31 March 2026 and 31 March 2025 are the balancing figures between audited figures in respect of the full financial year and the limited reviewed year to date figures up to the quarter ended 31 December 2025 and 31 December 2024 respectively.
- These audited consolidated financial results have been prepared in compliance with Ind AS as notified by the Ministry of Corporate Affairs and prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder and other accounting pronouncements generally accepted in India, to the extent applicable.
- Effective 21 November 2025, The Government of India has consolidated multiple existing labour laws into an unified framework comprising four Labour Codes viz the Code on Wages, 2019, the Code on Social Security, 2020, the Industrial Relations Code, 2020, and the Occupational Safety, Health and Working Conditions Code, 2020 collectively referred to as the 'New Labour Codes'. The Ministry of Labour & Employment published draft Central Rules and FAQs to enable assessment of the financial impact due to changes in regulations.

The Group has assessed the incremental impact of these changes on the basis of the information available and actuarial valuation report obtained from an independent valuer, consistent with the guidance provided by the Institute of Chartered Accountants of India. Considering the materiality, its origination due to regulatory changes and non-recurring nature of this impact, the Group has presented such incremental impact as "Exceptional Items" in the audited consolidated financial results for the year ended 31 March 2026. Accordingly the Exceptional Items includes of Rs. 4.20 Crores as incremental impact of Gratuity arising primarily due to the change in the definition of wages.

Further Exceptional Items also include Rs. 1.96 Crores which are non recurring costs associated with restructuring of capital during the year ended 31 March 2026.



6 During the quarter and year ended 31 March 2026, the Holding Company has forfeited 5,196 equity stock options and 25,172 equity stock options respectively granted to employees under Employee Stock Option schemes but not vested on account of discontinuance of services of these employees, which has been added back to the pool and the same would be available for subsequent distribution subject to statutory rules and regulations, as applicable.

During the year ended 31 March 2026, the Holding Company has allotted 63,074 equity shares of Rs.10/- each pursuant to the exercise of

7 The earning per share in respect of previous quarters / years has been restated considering the allotment of bonus shares and adjustment in respect of outstanding stock options, in line with the requirements of Ind AS 33 "Earnings Per Share".

8 The audited consolidated financial results are available on the website of the Company ([www.thyrocare.com](http://www.thyrocare.com)) and on the websites of BSE ([www.bseindia.com](http://www.bseindia.com)) and NSE ([www.nseindia.com](http://www.nseindia.com)).

By order of the Board

**For Thyrocare Technologies Limited**  
CIN - L85110MH2000PLC123882



**Rahul Guha**  
**Managing Director**  
DIN - 09588432  
Navi Mumbai, 7 May 2026



Tests you can trust

Annexure-2

May 07, 2026

To,  
National Stock Exchange of India Limited  
Exchange Plaza  
Bandra Kurla Complex,  
Bandra (E), Mumbai - 400051  
(SYMBOL: THYROCARE)

BSE Limited  
Phiroze Jeejeeboy Towers  
Dalal Street,  
Mumbai- 400001  
(SCRIP CODE: 539871)

**Subject: Declaration with respect to Unmodified Opinion on Audited Financial Results of the Company for the quarter and financial year ended March 31, 2026.**

Dear Sir/Madam,

I, Vikram Gupta, Chief Financial Officer of the Company, hereby declare that M/s. M S K A & Associates, Chartered Accountants, Statutory Auditors of the Company have issued unmodified opinion/unqualified opinion on the Audited Standalone and Consolidated Financial Results for the quarter and year ended March 31, 2026.

This declaration is given in accordance with Regulation 33(3)(d) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Kindly take the same on record.

Thanking you,

Yours Faithfully,  
For Thyrocare Technologies Limited,

  
Vikram Gupta  
Chief Financial Officer

Thyrocare Technologies Limited

📍 D-37/1, TTC MIDC, Turbhe, Navi Mumbai- 400 703, India 📞 022- 3090 0000

✉ info@thyrocare.com 🌐 www.thyrocare.com

/CIN : ISE110MH7000PLC122921